The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX)

The Manufacturers Life Insurance Company purchased a new stake in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,383 shares of the company’s stock, valued at approximately $90,000.

Several other institutional investors also recently bought and sold shares of TCRX. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics during the 2nd quarter worth approximately $70,000. American Century Companies Inc. boosted its stake in shares of TScan Therapeutics by 48.9% in the second quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after purchasing an additional 15,596 shares during the period. Cannon Global Investment Management LLC purchased a new position in shares of TScan Therapeutics in the first quarter valued at $139,000. Vanguard Group Inc. grew its holdings in TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new stake in TScan Therapeutics during the 2nd quarter worth $134,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock opened at $5.37 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. TScan Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $9.69. The firm’s 50-day simple moving average is $5.54 and its 200-day simple moving average is $6.78.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. Equities research analysts forecast that TScan Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on TCRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Monday, August 12th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.00.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of TScan Therapeutics stock in a transaction dated Monday, September 23rd. The shares were bought at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the transaction, the director now owns 45,000 shares in the company, valued at $238,050. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the purchase, the director now directly owns 45,000 shares in the company, valued at $238,050. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders acquired a total of 15,000 shares of company stock worth $82,550 over the last 90 days. Insiders own 2.76% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.